SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post-Offer Advertisement in accordance with Regulation 18(12) of the Securities and Exchange Board of ....

September 1, 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra Mumbai- 400001, India. (E), Mumbai – 400 051, India. Dear Sir / Madam, Subject: Open offer for acquisition of up to 2,77,26,848 (Two Crore Seventy-Seven Lakh Twenty-Six Thousand Eight Hundred Forty-Eight) fully paid-up equity shares of face value of ₹ 1 (Indian Rupee One) each (the “Equity Shares”), of Bliss GVS Pharma Limited (“Target Company”), representing 26.00% (Twenty-Six per cent) of the Expanded Voting Share Capital from the eligible public shareholders of the Target Company by Anupam Rasayan India Limited (“Acquirer”) along with Mates Visa Consultancy Private Limited (“PAC”) in its capacity as person acting in concert with the Acquirer pursuant to and in compliance with the requirements of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended (the “SEBI (SAST) Regulations”) (the “Open Offer”/“Offer”). This is with respect to the captioned Open Offer, in accordance with 18(12) of SEBI (SAST) Regulations please find enclosed a copy of the post offer advertisement dated August 31, 2026 (“Post-Offer Advertisement”) that has appeared in following newspapers on September 1, 2026. Newspaper Language Editions The Financial Express English All editions Jansatta Hindi All editions Navshakti Marathi Mumbai edition Capitalized terms used in this letter unless defined herein shall have the same meanings as ascribed to them in the LOF. Kindly take the enclosed Post-Offer Advertisement on record and disseminate the same on your website. For and on behalf of SBI Capital Markets Limited Authorized Signatory Name: Sylvia Mendonca Place: Mumbai Registered Office: SBI Capital Markets Limited, 1501, 15th floor, A & B Wing, Parinee Crescenzo Building, G Block, Bandra Kurla Complex, Bandra East, Mumbai- 400 051 | Tel: 4196 8300 | Email: corporate.office@sbicaps.com Web: www.sbicaps.com | CIN: U99999MH1986PL040298 A Subsidiary of State Bank of India Size: 12 x 50 cm POST-OFFER ADVERTISEMENT IN ACCORDANCE WITH REGULATION 18(12) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AS AMENDED, FOR THE ATTENTION OF THE PUBLIC SHAREHOLDERS OF BLISS GVS PHARMA LIMITED Registered Offi ce: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai, Maharashtra - 400072 Corporate Identifi cation Number (CIN): L24230MH1984PLC034771 Tel: 022-42160000; Email address: Project.compliance@blissgvs.com; Website: www.blissgvs.com Open offer for acquisition of up to 2,77,26,848 (two crore seventy-seven lakh twenty-six thousand eight hundred forty- eight) fully paid-up equity shares of face value of ₹ 1 (Indian Rupee One) each of Bliss GVS Pharma Limited (“Target Company”) (“Offer Shares”), representing 26.00% (twenty-six per cent) of the Expanded Voting Share Capital of the Target Company from the Public Shareholders (as defi ned below) by Anupam Rasayan India Limited (“Acquirer”) together with Mates Visa Consultancy Private Limited as the person acting in concert with the Acquirer (“PAC”), pursuant to and in compliance with the requirements of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (the “SEBI (SAST) Regulations”) (the “Open Offer”/ “Offer”). This post-offer advertisement is being issued by SBI Capital Markets Limited, the manager to the Open Offer (“Manager”), on behalf of the Acquirer and the PAC in connection with the Open Offer to the Public Shareholders of the Target Company, pursuant to and in compliance with Regulation 18(12) of the SEBI (SAST) Regulations (“Post Offer Advertisement”). The detailed public statement, dated 30 May 2026 with respect to the aforementioned Open Offer was published on 1 June 2026 (“Detailed Public Statement”) in: (i) all editions of The Financial Express (English); (ii) all editions of Jansatta (Hindi); and (iii) the Mumbai edition of Navshakti (Marathi) (“Newspapers”) by the Manager on behalf of the Acquirer, in compliance with the SEBI (SAST) Regulations. This Post Offer Advertisement should be read in continuation of, and in conjunction with the: (a) Public announcement dated 23 May 2026 (“Public Announcement”); (b) Detailed Public Statement dated 30 May, 2026 (“Detailed Public Statement”); (c) Draft letter of offer dated 8 June 2026 (“Draft Letter of Offer”); (d) Addendum to the Public Announcement, Detailed Public Statement and Draft Letter of Offer, dated 17 July 2026 published in the Newspapers on 18 July 2026 (“Addendum”); (e) Letter of offer dated 18 July 2026 along with the Form of Acceptance-cum-Acknowledgement (“Letter of Offer”); and (f) Pre-offer advertisement cum corrigendum to the Detailed Public Statement dated 24 July 2026 (“Pre-Offer Advertisement cum Corrigendum”), published in the Newspapers on 27 July 2026. This Post Offer Advertisement is being published in all the Newspapers in which the Detailed Public Statement was published. Capitalised terms used but not defi ned in this Post Offer Advertisement shall have the same meaning assigned to such terms in the Letter of Offer and the Pre-Offer Advertisement cum Corrigendum. 1. Name of the Target Company: Bliss GVS Pharma Limited 2. Name of the Acquirer and PAC: Acquirer: Anupam Rasayan India Limited PAC: Mates Visa Consultancy Private Limited 3. Name of the Manager to the Offer: SBI Capital Markets Limited 4. Name of the Registrar to the Offer: MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) 5. Offer Details: (a) Date of Opening of the Offer: Tuesday, 28 July 2026 (b) Date of Closure of the Offer: Monday, 10 August 2026 6. Date of Payment of Consideration: Monday, 24 August 2026 7. Details of Acquisition: Particulars Proposed in the Offer Document Actuals 1 Offer Price ₹ 299.00 per Offer Share ₹ 299.00 per tendered share 2 Aggregate number of shares tendered 2,77,26,848(1) 1,669(4) 3 Aggregate number of shares accepted 2,77,26,848(1) 1,669(4) 4 Size of the Offer (Number of shares ₹829,03,27,552, being the maximum ₹4,99,031 being the consideration multiplied by Offer Price per share) consideration payable pursuant paid for the 1,669 Equity Shares to the Open Offer assuming full acquired pursuant to the Open acceptance of the Equity Shares Offer. tendered in the Offer.(1) 5 Shareholding of the Acquirer and the PAC Acquirer: Acquirer: before Agreements/Public Announcement Nil (0.00%) Nil (0.00%) (No. of Equity Shares and % of the equity PAC: PAC: share capital) Nil (0.00%) Nil (0.00%) 6 Shares Acquired by way of Agreements Acquisition of a minimum of Acquirer: • Number 4,58,03,024 Equity Shares (42.95% Nil(0.00%)(2)(3)(5) • % of the Expanded Voting Share Capital of the Expanded Voting Share PAC: Capital of the Target Company as Nil (0.00%)(2)(3)(5) on date).(2)(3)(5) 7 Shares Acquired by way of Open Offer Acquirer: Acquirer: • Number Nil (0.00%) 1,669 (0.00%)(4) • % of Expanded Voting Share Capital PAC: PAC: 2,77,26,848 (26.00%)(1)(4) Nil (0.00%)(4) 8 Shares acquired after Detailed Public Acquirer: Acquirer: Statement Nil (0.00%) Nil (0.00%) • Number of shares acquired PAC: PAC: • Price of the shares acquired Nil (0.00%) Nil (0.00%) • % of equity share capital 9 Post Offer shareholding of the Acquirer Acquirer: Acquirer: • Number Nil (0.00%) 1,669(0.00%)(4) • % of the Expanded Voting Share Capital PAC: PAC: 2,77,26,848 (26.00%) Nil (0.00%) 10 Pre and Post Offer shareholding of the Pre-Offer: Pre-Offer: Public Shareholders 5,56,49,027 (52.18%) 5,56,49,027 (52.18%) • Number Post-Offer: Post-Offer: • % of Expanded Voting Share Capital 2,79,22,179 (26.18%)(1) 5,56,47,358 (52.18%) (1) Assuming full acceptance under the Open Offer. (2) In terms of the SPA, in addition to the acquisition of a minimum of 4,58,03,024 Equity Shares (Base Shares) which represent 43.11% of the equity s [Showing first 8,000 characters — download PDF for full document]